Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466689 | 0.87 | HSD11B1 (0.48) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL5468420 | 0.85 | HSD11B1 (0.48) | HSD11B1PANK3GPR119SMOCHRM1 | |
| SCHEMBL5468233 | 0.84 | HSD11B1 (0.51) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL14581841 | 0.83 | HSD11B1 (0.45) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL14581827 | 0.83 | HSD11B1 (0.49) | HSD11B1CHRM1 | |
| SCHEMBL5481967 | 0.82 | HSD11B1 (0.51) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL14581838 | 0.81 | HSD11B1 (0.48) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL14581819 | 0.80 | KDM4E (0.52) | HSD11B1PANK3GPR119PARP1SMO | |
| SCHEMBL5466940 | 0.78 | PANK3 (0.40) | HSD11B1PANK3GPR119SMOCHRM1 | |
| SCHEMBL12640412 | 0.78 | HSD11B1 (0.49) | HSD11B1PANK3GPR119PARP1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
| WO-2006106423-A2 | AMINO SULFONYL DERIVATIVES AS INHIBITORS OF HUMAN 11-.BETA.-HYDROSYSTEROID DEHYDROGENASE | PFIZER INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | HSD11B1 1/4885PANK3 2984/4885GPR119 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.